Skip to content
value.today

Protek: peers

Change the peers

Protek beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Protek, MD Medical Group Investments, InMode Ltd., Adlai Nortye, Korian: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Protek, Pharmacy Chain 36.6, MD Medical Group Investments, Corvus Pharmaceuticals, Inc., InMode Ltd., Adlai Nortye, Korian, MoonLake Immunotherapeutics side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureProtekbase
PRTK.ME · 🇷🇺 RU
Percentile in Healthcare
Percentile in Russia
Pharmacy Chain 36.6
APTK.ME · 🇷🇺 RU
Percentile in Healthcare
Percentile in Russia
MD Medical Group Investments
MD6B.F · 🇷🇺 RU
Percentile in Healthcare
Percentile in Russia
Corvus Pharmaceuticals, Inc.
CRVS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
InMode Ltd.
INMD · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
Adlai Nortye
ANL · 🇰🇾 KY
Percentile in Healthcare
Percentile in Cayman Islands
Korian
KORI.PA · 🇫🇷 FR
Percentile in Healthcare
Percentile in France
MoonLake Immunotherapeutics
MLTX · 🇨🇭 CH
Percentile in Healthcare
Percentile in Switzerland
Group median
Size
Market cap (Better neither way: ranked highest first)$846 Mlast known, Jan 1, 2020 · Market dataLast known value: no current one4th of 8$661 MNov 19, 2026 · Market data7th of 8$216 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one8th of 8$863 MOct 21, 2026 · Market data1st of 8$859 MAug 1, 2026 · Market data2nd of 8$853 MAug 1, 2026 · Market data3rd of 8$830 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8$830 MOct 20, 2026 · Market data6th of 8$838 M8 ranked
Revenue (Better neither way: ranked highest first)$4.4 BFY2017 · Wikidata2nd of 3——————$371 MFY2025 · SEC3rd of 3——$6.0 BFY2025 · ESEF1st of 3——$4.4 B3 ranked
Net income (Higher is better)$101 MFY2017 · Wikidata1st of 6————$-15 MFY2025 · SEC4th of 6$94 MFY2025 · SEC2nd of 6$-52 MFY2024 · SEC5th of 6$2 MFY2025 · ESEF3rd of 6$-227 MFY2025 · SEC6th of 6$-7 M6 ranked
Employees (Better neither way: ranked highest first)12,0002012 · Profile2nd of 4————37December 31, 2025 · Profile4th of 4660December 31, 2025 · Profile3rd of 4——57,5182022 · Profile1st of 4——6,3304 ranked
Growth
Revenue growth (Higher is better)————————————————-6.2%FY2025 · SEC2nd of 216th20th————+4.7%FY2025 · ESEF1st of 236th56th————-0.7%2 ranked
Revenue growth, 3 years a year (Higher is better)————————————————-6.6%FY2025 · SEConly one with it15th20th————————————-6.6%—
Earnings per share growth (Higher is better)————————————————-36.4%FY2025 · SEConly one with it13th34th————————————-36.4%—
Margins and returns
Gross margin (Higher is better)————————————————78.5%FY2025 · SEConly one with it79th86th————————————78.5%—
Operating margin (Higher is better)————————————————23.1%FY2025 · SEC1st of 291st92nd————5.7%FY2025 · ESEF2nd of 266th52nd————14.4%2 ranked
Net margin (Higher is better)————————————————25.3%FY2025 · SEC1st of 292nd93rd————0.0%FY2025 · ESEF2nd of 260th30th————12.7%2 ranked
Free cash flow margin (Higher is better)————————————————22.8%FY2025 · SEConly one with it91st83rd————————————22.8%—
Return on equity (Higher is better)————————————-32.6%FY2025 · SEC3rd of 552nd23rd13.5%FY2025 · SEC1st of 586th79th-103.2%FY2024 · SEC5th of 524th—0.0%FY2025 · ESEF2nd of 573rd25th-60.5%FY2025 · SEC4th of 538th12th-32.6%5 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————————————9.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————————————
Price to sales (Better neither way: ranked highest first)————————————————2.3×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————————————
Price to book (Better neither way: ranked highest first)————————————14.1×price Oct 21, 2026 · Market data1st of 289th93rd1.3×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price33.5×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————2.7×price Oct 20, 2026 · Market data2nd of 246th—8.4×2 ranked
Free cash flow yield (Higher is better)————————————-3.8%price Oct 21, 2026 · Market data1st of 257th29th9.8%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-6.1%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————-23.6%price Oct 20, 2026 · Market data2nd of 230th—-13.7%2 ranked
Financial strength
Debt to equity (Lower is better)————————————————————————————0.2×FY2025 · SEConly one with it35th62nd0.2×—
Interest cover (Higher is better)————————————————————-27.3×FY2024 · SEConly one with it28th—————————-27.3×—
Scorecard
Scorecard (Higher is better)——————1 of 14FY2025 · Scorecard5th of 58 of 16FY2025 · Scorecard2nd of 51 of 7FY2024 · Scorecard4th of 53 of 5FY2025 · Scorecard1st of 54 of 13FY2025 · Scorecard3rd of 531% passed5 ranked
Valuation checks (Higher is better)——————0 of 4FY2025 · Scorecard2nd of 2——————1 of 4FY2025 · Scorecard1st of 213% passed2 ranked
Growth checks (Higher is better)——————0 of 2FY2025 · Scorecard3rd of 51 of 6FY2025 · Scorecard2nd of 50 of 1FY2024 · Scorecard3rd of 52 of 2FY2025 · Scorecard1st of 50 of 1FY2025 · Scorecard3rd of 50% passed5 ranked
Profitability checks (Higher is better)——————0 of 3FY2025 · Scorecard3rd of 53 of 5FY2025 · Scorecard1st of 50 of 2FY2024 · Scorecard3rd of 51 of 3FY2025 · Scorecard2nd of 50 of 3FY2025 · Scorecard3rd of 50% passed5 ranked
Financial health checks (Higher is better)——————1 of 2FY2025 · Scorecard3rd of 43 of 3FY2025 · Scorecard1st of 41 of 3FY2024 · Scorecard4th of 4——3 of 4FY2025 · Scorecard2nd of 463% passed4 ranked
Shareholder returns checks (Higher is better)——————0 of 3FY2025 · Scorecard2nd of 41 of 2FY2025 · Scorecard1st of 40 of 1FY2024 · Scorecard2nd of 4——0 of 1FY2025 · Scorecard2nd of 40% passed4 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——————81.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 454.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 447.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4——85.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 468.2%4 ranked
Institutions holding (Better neither way: ranked highest first)——————1772026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 41922026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4522026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4——1692026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 41734 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——————+0.6 pp2026-Q2 against 2026-Q1 · 13F2nd of 3+3.6 pp2026-Q2 against 2026-Q1 · 13F1st of 3————+0.3 pp2026-Q2 against 2026-Q1 · 13F3rd of 3+0.6 pp3 ranked
Dividends
Dividend yield (Higher is better)————————————0.0%FY2025 · SEConly one with it6th2nd————————————————0.0%—
Shareholder yield (Higher is better)————————————0.0%FY2025 · SEConly one with it7th3rd14.8%FY2025 · SECnot ranked: old priceold priceold price————————————0.0%—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Protek: Moscow Exchange, issue size times the close; Pharmacy Chain 36.6: Moscow Exchange, issue size times the close; MD Medical Group Investments: How market caps are worked out; Corvus Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; InMode Ltd.: How market caps are worked out; Adlai Nortye: How market caps are worked out; Korian: How market caps are worked out; MoonLake Immunotherapeutics: How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Protek———
Pharmacy Chain 36.6———
MD Medical Group Investments———
Corvus Pharmaceuticals, Inc.———
InMode Ltd.23.1%FY2025
91st percentile in Healthcaremedian -7.7%, 674 companies
92nd percentile in Israelmedian -0.2%, 67 companies
Adlai Nortye———
Korian5.7%FY2025
66th percentile in Healthcaremedian -7.7%, 674 companies
52nd percentile in Francemedian 5.5%, 124 companies
MoonLake Immunotherapeutics———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$1.5 B$3.0 B$4.5 B$6.0 B20182019202020212022202320242025InMode Ltd. $371 MAdlai Nortye $5 MKorian $6.0 B

Rank in the group

1st2nd20172021202320242025Protek: 1st of 2 in 2017ProtekInMode Ltd.: 2nd of 2 in 2017InMode Ltd.: 1st of 2 in 2021InMode Ltd.: 1st of 2 in 2023InMode Ltd.: 2nd of 2 in 2024InMode Ltd.: 2nd of 2 in 2025InMode Ltd.Adlai Nortye: 2nd of 2 in 2021Adlai Nortye: 2nd of 2 in 2023Adlai NortyeKorian: 1st of 2 in 2024Korian: 1st of 2 in 2025Korian
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearProtekPharmacy Chain 36.6MD Medical Group InvestmentsCorvus Pharmaceuticals, Inc.InMode Ltd.Adlai NortyeKorianMoonLake Immunotherapeutics
2025————$371 MSEC2nd—$6.0 BESEF1st—
2024————$395 MSEC2nd—$5.7 BESEF1st—
2023————$492 MSEC1st$5 MSEC2nd——
2022————$454 MSEC———
2021————$358 MSEC1st$46 MSEC2nd——
2020————$206 MSEC———
2019————$156 MSEC———
2018————$100 MSEC———
2017$4.4 BWD1st———$53 MSEC2nd———

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Protek#

Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Pharmacy Chain 36.6APTK.ME · 🇷🇺 Russia
    Same sector: Healthcare (Retail - Pharmacy) · Similar size: $661 M market cap against $846 M · Same country: Russia
    Market cap $661 M (Nov 19, 2026)
    68 of 100 (industry or sector 25 + size 28 + country 15)
    In the group
  • MD Medical Group InvestmentsMD6B.F · 🇷🇺 Russia
    Same sector: Healthcare (Medical Care Facilities) · Similar size: $216 M market cap against $846 M · Same country: Russia
    Market cap $216 M (last known, Jul 30, 2023)
    61 of 100 (industry or sector 25 + size 21 + country 15)
    In the group
  • Corvus Pharmaceuticals, Inc.CRVS · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $863 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $863 M (Oct 21, 2026)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    In the group
  • InMode Ltd.INMD · 🇮🇱 Israel
    Same sector: Healthcare (Medical Devices) · Similar size: $859 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $859 M (Aug 1, 2026) · revenue $371 M (year to December 2025)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    In the group
  • Adlai NortyeANL · 🇰🇾 Cayman Islands
    Same sector: Healthcare (Biotechnology) · Similar size: $853 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $853 M (Aug 1, 2026)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    In the group
  • KorianKORI.PA · 🇫🇷 France
    Same sector: Healthcare (Medical Care Facilities) · Similar size: $830 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $830 M (last known, Jul 30, 2023) · revenue $6.0 B (year to December 2025)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    In the group
  • MoonLake ImmunotherapeuticsMLTX · 🇨🇭 Switzerland
    Same sector: Healthcare (Biotechnology) · Similar size: $830 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $830 M (Oct 20, 2026)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    In the group
  • Ardelyx, Inc.ARDX · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $822 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $822 M (Oct 9, 2026) · revenue $407 M (year to December 2025)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    + Add
  • Arjo AB (publ)ARJO-B.ST · 🇸🇪 Sweden
    Same sector: Healthcare (Medical Distribution) · Similar size: $819 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $819 M (Aug 1, 2026) · revenue $1.1 B (year to December 2025)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    + Add
  • Gyre Therapeutics, Inc.GYRE · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $818 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $818 M (Oct 29, 2026) · revenue $117 M (year to December 2025)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    + Add
  • Pacific Biosciences of California, Inc.PACB · 🇺🇸 USA
    Same sector: Healthcare (Diagnostics and Research) · Similar size: $886 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $886 M (Oct 29, 2026) · revenue $160 M (year to December 2025)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    + Add
  • Kura Oncology, Inc.KURA · 🇺🇸 USA
    Same sector: Healthcare (Biotechnology) · Similar size: $884 M market cap against $846 M · Ratios of the last two fiscal years on file
    Market cap $884 M (Oct 27, 2026) · revenue $67 M (year to December 2025)
    60 of 100 (industry or sector 25 + size 30 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.